The Zhitong Finance App learned that Jetai Technology-P (07666) rose nearly 8% in early trading. As of press release, it rose 5.37% to HK$11.78, with a turnover of HK$15.984 million.

According to the news, on September 18, 10 departments including the Ministry of Industry and Information Technology jointly issued and implemented the “15th Five-Year Plan for the Development of the Pharmaceutical Industry”. The “Plan” clearly states “accelerate the development of large-scale pharmaceutical models and agents, create high-value application scenarios for AI pharmaceuticals around drug discovery, clinical research, etc., and accelerate the paradigm shift in pharmaceutical R&D and production management driven by artificial intelligence”; it is necessary to “focus on developing application scenarios such as AI-enabled target screening, drug molecule design and optimization, and auxiliary clinical trial plan review and scientific evaluation”.

According to public information, Jietai Technology has opened up the entire chain of AI molecular design, RNA code optimization, and accurate LNP delivery to accurate clinical implementation. The potential transaction scale for related cutting-edge therapies has reached the level of 6 billion yuan. The mRNA tumor vaccine pipeline also has plans to continue to expand. The commercial growth rate is likely to far exceed industry expectations. Furthermore, the commercialization results of Jietai Technology's NanoForge have entered a centralized release period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.